The novel finding that BET inhibitors (or BRD4 degraders) have the ability to repress the expression of this gene, together with the observation that reduced expression of MEIS2 can increase selected activities of IMiDs, further extends the current knowledge on the anticancer potential of these drugs and suggest that strategies aimed to target the expression/function of this protein could improve therapeutical approaches in MM. The gene discussed is BRD4; the disease is Miyoshi myopathy.